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Nanotechnology is an exciting and promising scientific discipline. At the nanoscale, a material displays novel physical
properties that offer many new and beneficial products and applications. In particular, magnetic nanoparticles - a
core/shell nanoparticle - present considerable diagnostic and therapeutic potentials, and superparamagnetic iron
oxide nanoparticles (SPIONs) are considered promising theranostic tools. Alzheimer's disease (AD) is a neurodegenerative
disorder that predominantly affects people over 65 years of age. The disease is characterized by the presence of
extracellular plaques in the brain which are formed by interwoven fibrils composed of variants of the β-amyloid
peptide. Medication can temporarily retard worsening of symptoms, but only in the first stages of the disease; early
detection is thus of crucial importance. This minireview covers the progress made in research on the use of magnetic
nanoparticles for ex vivo and/or in vivo detection and diagnosis of AD by means of magnetic resonance imaging (MRI),
or to label peptides and fibrils. Of particular importance is the use of these nanoparticles to detect AD biomarkers in
biological fluids. A description is given of the bio-barcode amplification assay using functionalized magnetic particles,
as well as the use of such nanoparticles as a system for inhibiting or delaying the assembly of peptide monomers into
oligomers and fibrils. Lastly, a brief overview is given of possible future lines of research in this.
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Introduction
Alzheimer's disease (AD) is a devastating neurodegener-
ative disorder that predominantly affects people over
65 years of age. The two main pathophysiological hall-
marks of AD are the presence in the brain of extracellu-
lar amyloid plaques and of intracellular neurofibrillary
tangles composed of hyperphosphorylated tau proteins.
Although a causal relationship between amyloid deposits
and the development of AD has not been conclusively
demonstrated, a considerable body of experimental data
suggests that amyloid aggregates are important in the
etiology of AD [1-4]. The formation of such deposits is
seen as the beginning of the neurodegenerative cascade
that eventually leads to neurotoxicity, oxidative stress,
and neuroinflammation. The amyloid core of these plaques* Correspondence: joanestelrich@ub.edu
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in any medium, provided the original work is pconsists of interwoven fibrils composed of β-amyloid (Aβ)
peptide variants and surrounded by dead neurons. Aβ var-
ies from 39 to 43 amino acids in length, the most abundant
forms being 40 and 42 amino acids [5]. The initiating event
of fibril formation is peptide misfolding, which leads to
acquisition of the capacity to aggregate in an infinitely
propagating fashion. Soluble spherical aggregates have
been observed over the course of fibril formation and it is
assumed that these spherical oligomers, usually called
amyloid-β derived diffusible ligands (ADDLs), appear as
intermediates in the pathway of fibril formation. Whereas
early evidence suggested that Aβ fibrils initiate a cascade of
events that result in neuronal cell death (amyloid cascade
hypothesis) [6], a number of researchers have proposed that
it is ADDLs, rather than monomers or insoluble amyloid
fibrils, that may be responsible for synaptic dysfunction in
AD (revised amyloid hypothesis) [7-11].
Although there is no cure, AD medications can tem-
porarily slow the worsening of symptoms and improve
the quality of life for those with Alzheimer's and their
caregivers. Of the five US Food and Drug Administrations an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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AD, four are cholinesterase inhibitors (AChE) and the fifth
is an N-methyl-D-aspartate (NMDA) receptor antagonist.
The AChE inhibitors work by slowing down the disease
activity that breaks down a key neurotransmitter. Donepe-
zil, galantamine, rivastigmine, and tacrine are AChE inhi-
bitors. Memantine is an NMDA that works by regulating
the activity of glutamate, a chemical messenger involved
in learning and memory. Memantine protects brain cells
against an excess of glutamate, released in large amounts
by cells damaged by AD and other neurological disorders.
The pharmacotherapy of AD offers primarily symp-
tomatic benefits, and there is little or no evidence that it
delays disease progression. Current research has there-
fore focused on identifying early detection and diagnosis
strategies, one of the most challenging and crucial areas
in modern medicine.
Nanotechnology is a multidisciplinary branch of science
which encompasses numerous diverse fields of science and
technology, ranging from biomedicine, pharmaceutics,
agriculture, environmental sciences, advanced materials,
chemical science, physics, electronics, information technol-
ogy, and so on. Nanotechnology uses engineered materials
or devices that have a functional organization on the nano-
meter scale in at least one dimension. The potential of
nanotechnological applications to the life sciences arises
from the fact that they exhibit bulk mesoscale and macro-
scale chemical and/or physical properties that are unique
to the engineered material or device and not necessarily
possessed by the molecules alone. The smaller size and
high surface-to-volume ratio of nanoparticles are the key
features which make them useful in biomedical fields,
facilitating the development of many new properties, ease
of functionalization, conjugation of biomolecules, etc. [12].
Nanodevices and nanomaterials aimed at biomedical appli-
cations are designed to interface and interact with bio-
logical systems at molecular levels with a high degree of
specificity. Thus, they can stimulate, respond to, and inter-
act with target cells and tissues in controlled ways to
induce desired physiological responses while minimizing
undesirable effects. With all this potential, nanotechnology
could have a revolutionary impact on therapy, and in
particular on AD diagnosis.
Nanoparticles used in biomedical applications include
liposomes, polymeric micelles, block ionomer complexes,
dendrimers, inorganic and polymeric particles, nanorods
and quantum rods [13]. At present, core-shell-structured
nanoparticles are used in preference to simple nanoparti-
cles for several biomedical applications because of their
additional advantages. Core-shell nanoparticles have a
core made of a material coated with another material. The
advantages of these nanoparticles over simple nanoparti-
cles include less toxicity, greater dispersibility, bio- and
cytocompatibility, better conjugation with other bioactivemolecules, and increased thermal and chemical stability
[14]. In this review, we present the promising perspectives
that nanotechnology, and more specifically magnetic
particles, offers in research on AD diagnosis.
Nanotechnology: magnetic particles
Among the diversity of available core-shell nanoparti-
cles, superparamagnetic nanoparticles coated with either
inorganic materials (silica, gold) or organic materials
(phospholipids, fatty acids, polysaccharides, peptides or
other surfactants and polymers) are promising candi-
dates for a wide range of biomedical applications. Fer-
rous or ferric oxide is the main constituent of magnetic
particles; ferromagnetic iron oxides, maghemite, γ-Fe2O3,
and magnetite, Fe3O4, are the most frequently used
materials and are also the only magnetic materials that are
FDA-approved for use in humans [15], although pure
transition metals such as cobalt and nickel are also
employed. The magnetic properties of superparamagnetic
iron oxide nanoparticles, known as SPIONs, are based on
their inducible magnetization, and they can be directed to
a defined location in the presence of an externally applied
AC magnetic field. This characteristic renders them
attractive for many applications, ranging from various
separation techniques and contrast-enhancing agents
for magnetic resonance imaging (MRI) to drug delivery
systems, as well as for magnetically assisted transfection of
cells.
Magnetic nanoparticles are promising theranostic
tools. They can be used in therapy (hyperthermia, local
chemotherapy, and magnetically guided photodynamic
therapy), drug delivery and diagnosis (for a review, see
[16]). Due to the lack of an early diagnostic and thera-
peutic approach, theranosis is of considerable interest in
AD, and SPIONs are considered particularly promising
candidates due to their unique biocompatible and mag-
netic properties and their capacity for multifunctional
application.
Research on the use of magnetic nanoparticles in AD
has focused on inhibiting β-peptide aggregation (according
to the amyloid cascade hypothesis) and ADDL formation
(if oligomers are thought to be responsible for initiating
AD), or on developing sensitive methods to quantify bio-
markers. It is in this latter field where the use of magnetic
nanoparticles has had most impact in neurology. Figure 1
summarizes the different diagnostic applications of mag-
netic nanoparticles in AD.
The blood–brain barrier: a challenge for nanotechnology
The main challenge in the diagnosis (and treatment) of
AD is to overcome the restrictive mechanism of the
blood–brain barrier (BBB). The BBB is the interface bet-
ween the blood and the brain and consists of a diffusion
barrier which impedes the influx of most compounds
Figure 1 Scheme of applications. Scheme of the diagnostic applications of magnetic particles in AD.
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elements of the brain microvasculature: endothelial
cells, astrocyte end-feet, and pericytes. BBB endothelial
cells differ from endothelial cells in the rest of the
body due to their absence of fenestrations, more
extensive tight junctions, and sparse pinocytic vesicle
transport [17]. Despite the extremely large surface area
of the 100 billion capillaries contained in the human
brain (approximately 20 m2), the permeability of many
substances is low because of the dense anatomical struc-
ture of tight junctions between endothelial cells around
the capillaries in the central nervous system (CNS).
These tight junctions are composed of smaller subunits,
frequently transmembrane proteins [18], each of which is
anchored to the endothelial cells by another protein com-
plex. This barrier does not exist in normal circulation,
but in the brain it limits the flux of hydrophilic molecules
across the BBB. In contrast, small lipophilic substances
such as water and some gases (O2, CO2) diffuse freely
across plasma membranes along their concentration
gradient, and nutrients crucial to neural function such as
glucose and amino acids enter the brain via transporters.
However, the BBB restricts the passage of solutes and
prevents the passage of most circulating cells and mole-
cules, thus protecting the brain from foreign substances
and maintaining CNS homeostasis [19]. Delivering thera-
peutic agents to the brain is a major challenge in the
treatment of most brain disorders. For instance, one way
of bypassing the BBB is the infusion of hyperosmolar so-
lutions (e.g., of mannitol) in conjunction with the suitable
drug. In consequence, one requirement for any substance
capable of detecting biomarkers or inhibiting β peptide
aggregation is that it should be able to cross the BBB.One particularly important area in which nanotech-
nology is applied to the CNS is in the development of
technologies and approaches for delivering drugs and
other small molecules such as genes, oligonucleotides,
and contrast agents across the BBB. An important ad-
vantage of a nanotechnological approach, as compared
with the administration of a free drug, is that the crucial
requirements needed to reach the CNS while producing
minimal systemic effects can be met by supporting parts
of the engineered complex.
Magnetic particles for AD diagnosis
Early diagnosis in AD before the onset of marked symp-
toms is critical to prevent irreversible neuronal damage
that eventually leads to dementia and ultimately death.
The clinical development of positron emission tomog-
raphy (PET) and single photon emission computed tom-
ography (SPECT) imaging agents that target aggregated
Aβ peptide deposits in vivo shows tremendous promise
for detecting changes in the accumulation of senile pla-
ques in living patients. Another important imaging tech-
nique which is potentially useful as a means to monitor
the pathological progression of AD is MRI. Despite the
relatively high quality of MR images of soft tissues, in
some cases it is not possible to acquire sufficient image
contrast to diagnose the pathology of interest. In such
cases, contrast agents are generally used, which shorten
the spin–lattice T1 and/or spin-spin T2 relaxation times
of the water protons within the tissues/regions to which
they are delivered, thus enhancing image contrast. Thus,
what is imaged is not the contrast agent but rather its
effect on the relaxivity of the adjacent water protons,
predominantly through dipolar interaction [20]. Since
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degeneration, most research has focused either on detec-
tion or identification of amyloid plaques, using SPIONs
as negative contrast agents. These decrease MR signal
intensity in the regions to which they are delivered, ren-
dering these regions darker in the image. Paramagnetic
substances such as gadolinium (Gd) are positive contrast
agents, enhancing MR signal intensity. However, due to
the toxicity associated with Gd-based contrast agents,
the focus of research has shifted to SPIONs. Moreover, a
more detailed analysis has shown that SPIONs also lead
to a shortening of T1, resulting in a positive contrast
[21]. To date, most formulations based on SPIONs have
been approved as MRI contrast agents by the Food and
Drug Administration as well as the European Medicines
Agency; however, at the present, many of them are being
taken off the market.
Conventional MRI contrast agents are generally only
effective in a single imaging mode of either T1 or T2,
and frequently present diagnostic ambiguities, especially
for small biological targets. The combination of simul-
taneously strong T1 and T2 contrast effects in a single
contrast agent could constitute a new breakthrough,
since it has the potential to provide more accurate MR
imaging. Due to strong magnetic coupling between T1
and T2 contrast agents when they are in close proximity,
the spin–lattice relaxation processes of T1 contrast ma-
terials are significantly diminished. One of the strategies
to overcome such a phenomenon is to locate the con-
trast agents in separate zones within the particle, for
instance, one in the core and the other in the shell
(Figure 2) [22].
In 1992, magnetite was found in the human brain [23]
and studies since then have associated elevated levels of
biogenic magnetite with both aging and AD [24-26]. AsFigure 2 Contrast agents used in MRI. Possible structure of a
nanoparticle containing both contrast agents. The thickness of the
separation layer controls magnetic coupling between T1 and T2
contrast materials.the magnetic susceptibility of magnetite is more than
two orders of magnitude higher than that of ferrihydrite
(the form in which most iron in the body is stored
within the ferritin protein), the forces acting on biogenic
magnetite particles in the body under the field and gra-
dient conditions present in the 7-T whole body scanner
and a 9.4-T small-bore research scanner have been stu-
died with the aim of determining the threshold for
effects on cellular ion channels. The results showed that
the effect of these forces on the biogenic particles did
not disrupt normal cellular function [27].
Magnetic nanoparticles are used as specific agents to
detect amyloid plaques in AD. To this end, the particles
must either be functionalized, for instance by incorpo-
rating antibodies against the Aβ on the particle's surface,
or bound to the Aβ peptide. As Aβ has an inherent af-
finity with amyloid plaques, these targeted agents could
selectively bind to amyloid plaques, thus enhancing
the contrast from surrounding tissues and enabling
plaque visualization by MRI. This approach was used
in the study by Wadghiri et al. [28], in which magnetic
nanoparticles covalently tethered to the N-terminus of
Aβ(1–40) through amide coupling were synthesized
for targeting and imaging of senile plaques in transgenic
mice using MRI when co-injected with mannitol used
to transiently open the BBB. In another in vivo study,
Sillerud et al. [29] synthesized antibody-conjugated
SPIONs targeted to the Aβ plaques in AD transgenic
mice and were able to cross the BBB and detect the
plaques in MR images; detectability was twofolds higher
than in control cases.
As indicated, antibody-targeted magnetic nanoparticles
have been used to detect Aβ plaques in AD. Following
this approach, Yang et al. [30] used SPIONs chemically
coupled with Aβ(1–42) to detect amyloid deposition
together with mannitol for in vivo μMRI by femoral
intravenous injection. The amyloid plaques detected
were confirmed with matched histological sections. Re-
sults were compared between AD transgenic and wild
mice for in vivo and ex vivo MRI brain imaging. Figure 3
compares the distribution of Aβ seen in histological sec-
tions with the matched patterns of hypointense spots.
Basing their study on the capacity of glycoconjugates
(e.g., gangliosides and anionic glycol polymers) to bind
Aβ [31], Kouyoumdjian et al. [32] have reported the
preparation of glyconanoparticles. These particles were
synthesized from dextran stabilized SPIONs. After the
introduction of amine groups, sialic groups were linked
to the SPIONs. The particles could selectively bind Aβ,
and the assembly was detected by MRI both in vitro and
ex vivo in mouse brains. Furthermore, the authors
indicated that besides being nontoxic to neuroblastoma
cells, the glyconanoparticles also reduced Aβ-induced
cytotoxicity to cells.
Figure 3 Images of amyloid plaques. Amyloid plaques detected with in vivo μMRI after intravenous femoral injection of SPIONs-Aβ(1–42) with
mannitol. In vivo T2*-weighted MRI images show a 14-month-old wild-type (A) and transgenic (B) mouse brain. Note the match of many large
plaques (arrowheads) in immunohistochemistry (D) and μMRI (B) in the AD transgenic mice. (C) Lack of plaque detection in a wild-type mouse
following SPION-Aβ(1–42) injection (from [30], with permission).
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visualized Aβ plaques with gadolinium diethylene-
triaminepentaacetic acid (GdDTPA) conjugated to a
putrescine-modified Aβ(1–40) capable of crossing the
BBB and targeting amyloid deposits in the brain of
transgenic mice. First, the Gd particles were incubated
with brain sections. Results in vitro showed that putrescine
modification enabled a dramatic increase in binding of Aβ
to the plaques. Then, Gd particles were administrated
intravenously to mice and Aβ plaques were labeled in
brains of postmortem specimens. The authors of this study
reported a more than ninefold enhancement (T1-weighted
images) in cortex and hippocampus regions in AD trans-
genic mice at 7 T. Petiet et al. [34] have described a new
method to detect amyloid plaques by means of in vivo
MRI based on the intracerebroventricular injection of a
non-targeted gadolinium-based contrast agent, which rap-
idly diffuses throughout the brain and increases the signal
and contrast of MR images. This gain in image sensitivity
after in vitro and in vivo gadolinium staining significantly
improved the detection and resolution of individual amyl-
oid plaques in the cortex and hippocampus of AD trans-
genic mice; furthermore, the improved image resolution
was sufficiently sensitive to demonstrate an age-dependent
increase in amyloid plaque load and a good correlation
between the amyloid load measured by μMRI and his-
tology. These results provided the first demonstration that
non-targeted Gd staining could enhance the detection
of amyloid plaques to monitor the progression of AD.
Martins et al. [35] conjugated an optimized derivative of
the Pittsburg compound-B (PiB), a well-established marker
of Aβ plaques, to DO3A-monoamide, which is capable offorming stable, non-charged complexes with Gd (and
other trivalent metal ions). Proton relaxivity evidenced
binding of Gd (DO3A-PiB) to Aβ(1–40), resulting in a
twofold increase in relaxivity as a consequence of im-
mobilization of the complex. Ex vivo immunochemical
studies showed that the DO3A-PiB complexes selectively
targeted Aβ plaques in AD human brain tissue.
In other cases, bare magnetic particles have been
utilized. Beckmann et al. [36] used SPIONs to noninva-
sively study microvascular lesions originated by cerebral
amyloid angiopathy (CAA), a pathology exhibited by
approximately 80% of the AD patients. CAA is charac-
terized by deposition of Aβ on the walls of cerebral
vessels, and is associated with hemorrhages ranging from
microbleeds to stroke, and with vasculitis presenting a
variable degree of lymphocyte infiltration and vascular
thickening. Both conditions are accompanied by the
presence of macrophages/microglia, which surround af-
fected vessels. Detecting such events in vivo can help to
better understand the role of CAA in the development
of dementia. Foci of signal attenuation were detected by
MRI in cortical and thalamic brain regions of aged
transgenic mice. Attenuation is the consequence of the
paramagnetic properties of the hemoglobin degradation
product hemosiderin. Histology confirmed that foci of
signal attenuation reflected an increase in CAA-related
lesions. In this study, magnetic particles were injected
intravenously to transgenic mice modeling AD. It was
observed that 24 h after particle administration, when
particles had been taken up by macrophages, the
strength and number of foci of signal attenuation had
increased. These results demonstrated that MRI in
Busquets et al. Nanoscale Research Letters 2014, 9:538 Page 6 of 10
http://www.nanoscalereslett.com/content/9/1/538combination with the administration of SPIONs im-
proves the detectability of CAA-related microvascular
lesions in transgenic mouse models of AD.
In an in vitro study, Skaat and Mergel [37] combined
magnetic and fluorescent imaging in one nanostructured
system, using maghemite nanoparticles bearing either
rhodamine or Congo red. The nanoparticles bound selec-
tively to Aβ(1–40) fibrils in both cases. The Aβ(1–40)-
nanoparticle assemblies thus formed were completely
removed by a magnetic field. This hybrid system might
enable the early detection of plaques and removal by
magnetization.
Ferromagnetic metals such as Fe, Co, and Ni possess
stronger magnetic moments than those of the currently
widely used iron oxide nanoparticles; however, they can-
not be used directly in biological applications due to their
high reactivity in aqueous environments. To address this
limitation, Choi et al. [38] described the synthesis of hete-
rodimeric nanoparticles consisting of a cobalt magnetic
core and a platinum shell directly fused to a gold nano-
particle (Co@Pt-Au). To obtain high colloidal stability and
target specificity, lipoic acid-polyethylene glycol (PEG)-
COOH complexes with disulfide ends that bind to the Au
surface were ligated to the Co@Pt-Au nanoparticles. The
terminal carboxyl groups of the PEG chains enabled cova-
lent binding with lysine residues of neutravidin on the sur-
face of the nanoparticles (Co@Pt-Au-neutravidin). These
nanoassemblies presented high magnetization values. The
MRI measurements of Co@Pt-Au-neutravidin nano-
particle samples mixed with an increasing amount of
biotinylated Aβ(1–40) peptides showed that significant
contrast changes took place when varying the peptide
concentration. The results clearly showed that these nano-
particles can be used in MRI to monitor key structuralFigure 4 The bio-barcode amplification assay. The assay uses magnetic
and bind ADDLs. The ADDLs are then sandwiched with a nanoparticle pro
antibody. After repeated washing while using a magnet to immobilize the
barcode DNA strands for each antigen-binding event (From [39]. Copyrightstages of Aβ self-assembly. In particular, a significant
change was observed in MRI signals during Aβ self-
aggregation that corresponded to the detection of Aβ
protofibrillar species in the early reversible stages of
aggregation.
There is no definitive diagnosis of the disease other than
postmortem identification of senile plaques and neurofib-
rillary tangles in the brain. Premortem diagnosis, based on
a patient's clinical history, in vivo brain imaging, and
neurophysiological, cognitive and neurological tests, is
only 85% accurate. There are two general approaches for
detecting soluble markers of AD. One approach is based
on measuring total τ protein or amyloid β-protein con-
centrations in cerebrospinal fluid (CSF) or plasma. This
approach is hampered by a significant overlap of such
marker levels in healthy and unhealthy subjects and has
led to inconclusive results. The other approach targets
only the suspected pathogenic markers, such as cleaved τ
protein, phosphorylated τ protein, or ADDLs. Although
this approach to detecting pathogenic markers might lead
to more definitive results, the concentrations of such
markers in CSF are so low in the early stages of the disease
that they cannot be identified accurately with conventional
ELISA or blotting assays [39]. This limitation can be
addressed by using the bio-barcode assay, an emerging
diagnostic tool based on advances in nanotechnology and
used for ultrasensitive enzyme-free detection of various
protein and nucleic acid targets. In the case of proteins,
the bio-barcode assay can be between one and six orders
of magnitude more sensitive than conventional ELISA-
based assays, depending on target and sample complexity
[40,41]. Georganopoulou et al. [39] have demonstrated
that the bio-barcode assay (Figure 4) can be used to deter-
mine approximate ADDL concentrations in CSF. The keyparticles functionalized with monoclonal antibodies that recognize
be, modified with double-stranded DNA and an anti-ADDL polyclonal
magnetic particles, a dehybridization step releases hundreds of
(2005) National Academy of Sciences, USA).
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isolation of specific antigens by means of a sandwich
process involving oligonucleotide-modified Au nanopar-
ticles (nanoparticles with bio-barcodes) and magnetic
nanoparticles, both functionalized with antibodies specific
to the antigen of interest. The increased sensitivity gained
derives mainly from very effective antigen sequestration
and the amplification process that occurs as a result of the
large number of barcode DNA strands released for each
antigen recognition and binding event. The results of this
study showed that ADDL levels in control subjects were
lower than in subjects diagnosed with AD, with ADDL
concentration medians in the two groups of ≈ 200 aM and
1.7 fM, respectively.
A collection of CSF samples requires lumbar puncture,
a relatively risky and uncomfortable process which is
therefore unsuitable for large-scale screening or repeated
sampling for long-term monitoring of disease progression.
Consequently, biomarkers in types of body fluid other
than CSF are necessary, and one of the most promising
body fluids is blood. However, biomarker concentrations
in blood are very low and detection requires ultrahigh-
sensitivity assay technologies [42]. The superconducting
quantum interference device (SQUID) immunogenetic re-
duction (IMR) assay makes it possible to measure plasma
biomarkers for diagnosis of AD since the association be-
tween the functionalized magnetic nanoparticles and the
target biomarkers involves a reduction in magnetic
susceptibility [43]. Yang et al. [44] prepared SPIONs
biofunctionalized with antibodies against Aβ(1–40) and
Aβ(1–42). In combination with the IMR technology, they
demonstrated that such particles had the capacity to label
Aβs specifically. In a further study by this same group
[42], magnetic nanoparticles were coated with antibodies
against Aβ(1–40), Aβ(1–42), and τ protein. The results
showed that Aβ(1–42) and τ protein concentrations in
healthy controls were significantly lower than those in pa-
tients with AD. Using this technology, the low detection
limit for amyloids and τ protein was found to be 1 to
10 pg/mL.
Dopamine is a neurotransmitter, a chemical released
by nerve cells to send signals to other nerve cells, and
has recently been considered as a possible biomarker of
AD. Basal dopamine levels are involved in basic brain
functions, and disturbed concentration levels of this
neurochemical have been associated with pathological
states such as AD. Hence, determination of dopamine
concentration levels plays an important role not only in
the treatment of the disease but also in the study of
basic brain functions. Ranc et al. [45] have presented a
method for rapid analysis of dopamine levels in artificial
CSF and mouse striatum samples. This method is based
on a nanocomposite composed of magnetite and silver
nanoparticles, the surface of which is modified with ironnitriloacetic acid, a dopamine selective compound. The
magnetic properties of this nanocomposite enable simple
separation of targeted molecules from a complex matrix
while the silver acts as a platform for surface-enhanced
Raman scattering (SERS). Rapid and simple quantitative
experiments show improved detection of dopamine
levels in biological assays at low femtomolar concentra-
tions. The comparative data obtained from clinical sam-
ples of mouse striatum show that magnetic SERS is a
strong alternative to conventional methods (HPLC-MS).
Magnetic particles in the treatment of AD
The pharmacotherapy of AD offers primarily symptomatic
benefits, but does not retard disease progression. Conse-
quently, researchers are seeking new ways to treat AD.
There are several promising drugs in development, in-
cluding use of enzymes to decrease Aβ production,
substances that increase Aβ clearance, immunotherapy,
enzymatic degradation of Aβ, inhibition of Aβ aggrega-
tion, antioxidants, anti-inflammatory drugs, statins, etc.
(for a review, see [46,47]). From among these approaches,
the inhibition of Aβ assembly has been considered the
primary therapeutic strategy for this neurodegenerative
disease. Any system considered for treating AD must pos-
sess the capacity to cross the BBB. To date, a large num-
ber of studies have described the effect of nanoparticulate
systems on Aβ fibrillation [48]. Fibril formation occurs by
means of nucleation-dependent kinetics where the forma-
tion of a critical nucleus is the key determining step, after
which fibrillation proceeds rapidly. An exogenous material
capable of reducing peptide toxicity may act by two op-
posite, postulated mechanisms: (1) by decreasing mono-
mer nucleation and hence blocking aggregation, which
would result in a reduction in the formation of ADDLs,
fibrils, and plaques; or (2) by disaggregating amyloid pla-
ques or fibrils. To date, it is the first mechanism (Figure 5)
that has received most attention [49].
The results obtained from studying the kinetics of the
process are inconclusive and extremely dependent on the
experimental conditions of the in vitro studies. For in-
stance, many years ago, it was demonstrated that cationic
surfactants had a dual effect on Aβ fibrillation [50]; they
could either accelerate or inhibit fibrillation depending on
the surfactant concentration. A similar effect has been de-
scribed for liposomes [51] and, more recently, for cationic
polystyrene nanoparticles [52]. Depending on the specific
ratio (i.e., between the peptide and particle concentration),
the kinetic effects on amine-modified polystyrene nano-
particles vary between acceleration of the fibrillation
process (at low particle surface area in solution) to inhi-
bition of the fibrillation process at high surface area. How-
ever, the sole effect of negative surfactants is to delay the
development of fibrils [53]. In contrast, Linse et al. [54]
have reported that nanoparticles such as copolymer
Figure 5 Effect of magnetic particles on the fibrillogenesis of amyloid. Schematic representation of the possible scenario of a reduction in
the toxic effects of Aβ. (A) Usual sequence from peptide to fibrils. (B) Peptide monomers are adsorbed onto the surface of SPIONs and the free
peptide concentration is thus lowered; consequently, the possibility of forming oligomers and fibrils is also reduced.
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bon nanotubes, enhance the possibility of the appearance
of a critical nucleus for fibril nucleation (referring to fibrils
from human β-macroglobulin but extensible to any amyl-
oid protein). Nanoparticles present high surface-to-volume
ratios, and this enormous surface means that proteins may
be bound onto the particle surface. The potentially high
concentration of protein adsorbed at the particle surface,
combined with the low dimensionality of the surface, can
enhance the probability of partially unfolded proteins com-
ing into frequent contact, promoting amyloid formation if
the protein is suitable.
There are only a few reports on the interaction of
SPIONs with amyloidogenic proteins in the literature,
and the majority of these focus on insulin amyloid fibril
formation. Only one of the reports [55] discusses the
effect of magnetic nanoparticles on Aβ fibrillation, and
more specifically, the effect of dextran polymer coating
charge and thickness (i.e., a single polymer layer or a
double polymer layer) on fibrillation kinetics. Depending
on the surface coating charge, a dual surface area-
dependent effect was observed, with lower concentra-
tions of SPIONs inhibiting fibrillation, whereas higher
concentrations enhanced the rate of Aβ fibrillation. Thecoating charge influenced the concentration at which
acceleratory effects were observed, with positive SPIONs
promoting fibrillation at significantly lower particle con-
centrations than either negatively charged or essentially
uncharged SPIONs. The authors concluded that SPIONs
designed for in vivo medical imaging applications should
preferentially use a negatively charged or uncharged
surface coating.
Conclusions
Magnetic nanoparticles with paramagnetic or superpara-
magnetic properties are promising nanodiagnostic mate-
rials. Among the magnetic nanoparticles, SPIONs are
excellent T2 contrast agents, although with an appro-
priately sized iron core and applied in moderate con-
centrations they also show a T1 contrast. Hence, due to
their high biocompatibility, superparamagnetic proper-
ties, and their high capacity for use as multimodal con-
trast agents, these functionalized magnetic nanoparticles
are considered the most promising magnetic nanopar-
ticles in nanomedicine, and more specifically, in the
diagnosis of AD. Moreover, as with other nanoparti-
culate systems, it has been suggested that SPIONs can
modulate the fibrillation process either by inhibiting
Busquets et al. Nanoscale Research Letters 2014, 9:538 Page 9 of 10
http://www.nanoscalereslett.com/content/9/1/538formation of the nucleus or by delaying transformation
of ADDLs into fibrils. In this case, SPIONs could clearly
be classified as theranostic agents. However, further
studies on the interaction of SPIONs and Aβ are neces-
sary to confirm the existence of such unique properties,
especially in vivo research on animal models and/or
in vitro research under more realistic conditions, for
example in the presence of serum proteins, since it has
been demonstrated that in a biological medium, the
protein corona modifies and alters the properties of
uncoated particles.
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